Larka acted as strategic advisor to ArchiMed on its investment in Clean Cells.
14 November 2018
Larka is pleased to announce that it performed the Strategic Due-Diligence for ArchiMed, the new majority shareholders of Clean Cells. Larka’s M&A division advised ArchiMed on strategy, commercial and business aspects of the transaction.
ArchiMed acquired a majority stake in Clean Cells, a leading European provider of contract biosafety testing and cell banking services to the biopharmaceutical industry.
Founded in 2000 and based in Boufféré, France, Clean Cells has grown its staff to 80 people in 2018. The Company started as a specialist provider of biosafety testing services to producers of all classes of biological medicines, including protein therapeutics, vaccines, gene & cell therapies, etc. Over the years, the Company has added a cell banking and virus seed stock business line in response to demand from its original customer base. The Company is developing also a CDMO business for the emerging field of phage therapy.
Larka’s M&A division performed the Strategic Due-Diligence to assist ArchiMed with its assessment of the Clean Cells acquisition opportunity. In addition, Larka’s Industry consulting division performed the Quality & Regulatory Due-Diligence.
Pierre-Anthony Brioir, Director at Larka, commented: ”We are proud to have collaborated as strategic advisors for the Clean Cells opportunity and are delighted the Company has agreed to partner with ArchiMed. The Company’s strategy to grow through innovation and international expansion is very promising. We are convinced that the ArchiMed team, which has deep knowledge of the industry, will help accelerate growth in the Company’s priority markets.
ArchiMed’s investment team included Loïc Kubitza, Ludovic Alonzi, Michael Sneijers, and Isaac Haq.
Pierre-Anthony Brioir, Director at Larka, +33 650-630-286, firstname.lastname@example.org
Adrien Chalmont, Manager at Larka, +33 621-006-115, email@example.com
Larka is a strategy consulting and M&A advisory firm, dedicated to the Biotech & Pharma industry since 1993, which combines high value-creation strategic advisory with in-depth industrial & technical expertise. With over 100 consultants, Larka helps Private Equity Firms, Pharma & Biotech companies, MedTech and Contractors – CROs, CDMOs, CMOs, CSOs - build valuable businesses all around the world.
ArchiMed is a healthcare private equity investment firm headquartered in Lyon. The 30-person team comprising 10 nationalities was founded in 2014 by former 3i Healthcare leaders as the first independent, Pan-European private equity group focused exclusively on the healthcare sector. ArchiMed invests in all healthcare sectors, including Medtech, Biopharma, and Care Services. Over the last 30 years, the ArchiMed partners have directly managed and invested in more than 40 healthcare companies throughout the world, with a combined value above €5bn. www.archimed-group.eu